Caris & Company Upgrades Genoptix (GXDX) to Buy
More News related to GXDX
- Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
- Auriga Reiterates a 'Buy' on Genoptix (GXDX); Unique Growth Story
- Genoptix (GXDX) Rops Q3 EPS by 21c; Guides Higher for FY09; 2010 Revs In-line
- Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Upgrades
- Shares of Brocade (BRCD) Outperforming as Oscar Gruss Upgrades to Buy
- Kinross (KGC) Jumps Higher as Gold Breaks $1,200, JPMorgan Upgrades to Overweight
- Raymond James Upgrades PSS World Medical (PSSI) to Outperform
- Capital One Southcoast Upgrades Penn Virginia (PVA) to Add; Turning Bullish After Data Release
- Raymond James Upgrades CPFL Energia S.A. (CPL) to Outperform
Caris & Company upgrades Genoptix (Nasdaq: GXDX) from Above Average to Buy with a $35 price target.
Genoptix, Inc. provides specialized laboratory service that focus on delivering diagnostic services in the United States.
Related Categories
UpgradesStocks Mentioned
+1.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
